- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atomEsters thereof
Patent holdings for IPC class C07D 209/28
Total number of patents in this class: 29
10-year publication summary
0
|
1
|
3
|
0
|
2
|
2
|
2
|
2
|
0
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Antibe Therapeutics Inc. | 21 |
3 |
Kyushu University, National University Corporation | 1654 |
2 |
Medical Therapies Limited | 8 |
2 |
Soochow University | 1738 |
2 |
Risen (Suzhou) Pharma Tech Co., Ltd. | 66 |
2 |
Lunella Biotech, Inc. | 104 |
2 |
Shanghai Junshi Biosciences Co., Ltd. | 112 |
2 |
Augusta University Research Institute, Inc. | 145 |
1 |
Cedars-Sinai Medical Center | 1162 |
1 |
Daiichi Sankyo Company, Limited | 1877 |
1 |
EMS S.A. | 15 |
1 |
F.I.S. Fabbrica Italiana Sintetici S.p.A. | 128 |
1 |
Lehigh University | 167 |
1 |
Medrx Co., Ltd. | 128 |
1 |
Nanoegg Research Laboratories, Inc. | 21 |
1 |
The Penn State Research Foundation | 1527 |
1 |
Piramal Enterprises Limited | 156 |
1 |
Rutgers, The State University of New Jersey | 1893 |
1 |
Universidade Estadual Paulista Julio de Mesquita Filho - Unesp | 36 |
1 |
Ripple Therapeutics Corporation | 34 |
1 |
Other owners | 1 |